Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 669-677

  Meropol, Neal J ^a   Porter, Michelle ^a   Blumenson, Leslie E ^a   Lindemann, Matthew J ^a   Perez, Raymond P ^a   Vaickus, Louis ^a   Loewen, Gregory M ^a   Creaven, Patrick J ^a   Wilkes, Kimberly A ^a   Giedlin, Martin A ^a,b   Caligiuri, Michael A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; HYPERGLYCEMIA; NATURAL KILLER CELL; OUTPATIENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADULT; AGED; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASMS;

EID: 15844364381     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., Seipp, C. A., and White, D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474-485, 1989.
2. Phillips, J. H., Gemlo, B. T., Myers, W. W., Rayner, A. A., and Lanier, L. L. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J. Clin. Oncol., 5: 1933-1941, 1987.
3. Smith, K. A. Lowest dose interleukin-2 immunotherapy. Blood, 81: 1414-1423, 1993.
4. Caligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., and Ritz, J. Functional consequences of interleukin-2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med., 171: 1509-1526, 1990.
5. Vlasveld, L. T., Rodenhuis, S., Rutgers, E. J. T., Dubbelman, A. C., Hilton, A. M., Batchelor, D., and Rankin, E. M. Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. Eur. J. Clin. Oncol., 20: 122-129, 1994.
6. Caligiuri, M. A., Murray, C., Soiffer, R. J., Klumpp, T. R., Seiden, M., Cochran, K., Cameron, C., Ish, C., Buchanan, L., Perillo, D., Smith, K., and Ritz, J. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J. Clin. Oncol., 9: 2110-2119, 1991.
7. Soiffer, R. J., Murray, C., Gonin, R., and Ritz, J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood, 84: 964-971, 1994
8. Cancer Therapy Evaluation Program, Common toxicity criteria. NCI decision of cancer treatment guidelines for reporting of adverse drug reactions. NIH Publications, July 6-9, 1989.
9. Stewart, C. C., and Stewart, S. J. Cell preparation for the identification of leukocytes, In: Z. Darzynkiewicz, J. P. Robinson, and H. A. Crissman (eds.), Methods in Cell Biology Series. pp. 40-59. New York: Academic Press, 1995.
10. Robenson, M. J., and Ritz, J. Biology and clinical relevance of human natural killer cells. Blood, 76: 2421-2438, 1990.
11. Caligiuri, M. A., Murray, C., Robenson, M. J., Wang, E., Cochran, K., Cameron, C., Schow, P., Ross, M. E., Klumpp, T. R., Soiffer, R. J., Smith, K. A., and Ritz, J. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin-2. J. Clin. Invest., 91: 123-132, 1993.
12. Robenson, M. J., Caligiun, M. A., Manley, T. J., Levine, H., and Ritz, J. Human natural killer cell adhesion molecules. J. Immunol., 145: 3194-3201, 1990.
13. Sharenberg, J. G. M., Stam, A. G. M., von Blomberg, B. M. E., Roest, G. J., Palmer, P. A., Franks, C. R., Meijer, C. J. L. M., and Scheper, R. J. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur. J. Cancer, 30A: 1804-1809, 1994.
14. Konrad, M. W., Hemstreet, G., Hersh, E. M., Mansell, P. W. A., Mertelsmann, R., Kolitz, J. E., and Bradley, E. C Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res., 50: 2009-2017, 1990.
15. Gustavson, L. E., Nadeau, R. W., and Oldfield, N. F. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer. J. Biol. Response Modif., 8: 440-449, 1989.
16. Whitehead, R. P., Ward, D., Hemingway, L., Hemstreet, G. P., III, Bradley, E., and Konrad, M. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res., 50: 6708-6715, 1990.
17. Thompson, J. A., Lee, D. J., Lindgren, C. G., Benz, L. A., Collins, C., Shuman, W. P., Levitt, D., and Fefer, A. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 lymphokine activated killer cells. Cancer Res., 49: 235-240, 1989.
18. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., White, D. E., and Steinberg, S. M. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst., 85: 622-632, 1993.
19. Lindemann, A., Brossart, P., Hoffken, K., Flabhove, M., Voliotis, D., Diehl, V., Hecker, G., Wagner, H., and Mertelsmann, R. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase IB study. Cancer Immunol. Immunother., 37: 307-315, 1993.
20. Caron, P. C., Lai, L. T., and Scheinberg, D. A. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin. Cancer Res., 1: 63-70, 1995.
21. Ziegler, L. D., Palazzolo, P., Cunningham, J., Janus, M., Itoh, K., Hayakawa, K., Hellstrom, I., Hellstrom, K. E., Nicaise, C., Dennin, R., and Murray, J. L. Phase I trial of murine monclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J. Clin. Oncol., 10: 1470-1478, 1992.
22. Triozzi, P. L., Kim, J. A., Martin, E. W., Young, D. C., Benzies, T., and Villasmil, P. M. Phase I trial of escalating doses of interleukin-Iβ in combination with a fixed dose of interleukin-2. J. Clin. Oncol., 13: 482-489, 1995.
23. Bluman, E. M., Lindemann, M. J., Porter, M. M., Pixley, L., Frankel, S. R., and Caligiuri, M. A. Low dose interleukin-2 (IL-2) expands natural killer (NK) cell populations in vivo by selective prevention of apoptosis (Abstract). Blood, 84 (Suppl. 1) 1139, 1994.
24. Sleijfer, D. T., Janssen, R. A. J., Buter, J., de Vries, E. G. E., Willemse, P. H. B., and Mulder, N. H. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J. Clin. Oncol., 10: 1119-1123, 1992.
25. Stein, R. C., Malkovska, V., Morgan, S., Galazka, A., Aniszewski, C., Roy, S. E., Shearer, R. J., Marsden, R. A., Bevan, D., Gordon-Smith, E. C., and Coombes, R. C. The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. Br. J. Cancer, 63: 275-278, 1991.
26. Lissoni, P., Barni, S., Ardizzoia, A., Andres, M., Scardino, E., Cardellini, P., Bitta, R. D , and Tancini, G. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma. Tumori, 79: 397-400, 1993.
27. Lissoni, P., Barni, S., Ardizzioa, A., Crispino, S., Paolorossi, F., Archili, C., Vaghi, M., and Tancini, G. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur. J. Cancer, 28: 92-96, 1992.
28. Buter, J., Sleijfer, D. T., van der Graaf, W. T. A., de Vries, E. G. E., Willemse, P. H. B., and Mulder, N. H. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin. Oncol., 20: 16-21, 1993.